{"id":"https://openalex.org/W4394091744","doi":"https://doi.org/10.6084/m9.figshare.24936807","title":"Supplementary materials: Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC","display_name":"Supplementary materials: Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC","publication_year":2024,"publication_date":"2024-01-03","ids":{"openalex":"https://openalex.org/W4394091744","doi":"https://doi.org/10.6084/m9.figshare.24936807"},"language":"en","primary_location":{"id":"pmh:oai:figshare.com:article/24936807","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_materials_Comparative_effectiveness_analysis_between_entrectinib_clinical_trial_and_crizotinib_real-world_data_in_i_ROS1_i_NSCLC/24936807","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},"volume":null,"type":"supplementary-materials","indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://figshare.com/articles/dataset/Supplementary_materials_Comparative_effectiveness_analysis_between_entrectinib_clinical_trial_and_crizotinib_real-world_data_in_i_ROS1_i_NSCLC/24936807","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034705456","display_name":"Robert Charles Doebele","orcid":"https://orcid.org/0000-0001-6728-6857","observed_orcids":["https://orcid.org/0000-0001-6728-6857"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Doebele, Robert C.","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6728-6857","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054828796","display_name":"Laura Mezquita P\u00e9rez","orcid":"https://orcid.org/0000-0002-1695-7494","observed_orcids":["https://orcid.org/0000-0002-1695-7494"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Perez, Laura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073889590","display_name":"Huong Trinh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Trinh, Huong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080636105","display_name":"Michael Martinec","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martinec, Michael","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085188200","display_name":"Reynaldo Martina","orcid":"https://orcid.org/0000-0002-1925-820X","observed_orcids":["https://orcid.org/0000-0002-1925-820X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martina, Reynaldo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113882339","display_name":"Todd Riehl","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Riehl, Todd","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080991347","display_name":"Matthew Krebs","orcid":"https://orcid.org/0000-0001-7540-3064","observed_orcids":["https://orcid.org/0000-0001-7540-3064"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Krebs, Matthew G.","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7540-3064","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053128814","display_name":"Neal J. Meropol","orcid":"https://orcid.org/0000-0001-6353-7364","observed_orcids":["https://orcid.org/0000-0001-6353-7364"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Meropol, Neal J","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6353-7364","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025997705","display_name":"William Bruce Wong","orcid":"https://orcid.org/0000-0002-6054-278X","observed_orcids":["https://orcid.org/0000-0002-6054-278X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wong, William B","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6054-278X","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5023655314","display_name":"Gracy Crane","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Crane, Gracy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/entrectinib","display_name":"entrectinib","score":0.9950000047683716},{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":1.0},{"id":"https://openalex.org/keywords/comparative-effectiveness","display_name":"comparative effectiveness","score":0.5659999847412109},{"id":"https://openalex.org/keywords/time-to-treatment-discontinuation","display_name":"time to treatment discontinuation","score":0.8339999914169312},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9890000224113464},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9959999918937683},{"id":"https://openalex.org/keywords/real-world-data","display_name":"real-world data","score":0.6629999876022339},{"id":"https://openalex.org/keywords/rare-tumor","display_name":"rare tumor","score":0.3190000057220459},{"id":"https://openalex.org/keywords/central-nervous-system-metastases","display_name":"central nervous system metastasis","score":0.5199999809265137},{"id":"https://openalex.org/keywords/treatment-beyond-progression","display_name":"treatment beyond progression","score":0.7409999966621399},{"id":"https://openalex.org/keywords/alk-inhibitors","display_name":"ALK inhibitors","score":0.38199999928474426}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9354716539382935},{"id":"https://openalex.org/C2775999482","wikidata":"https://www.wikidata.org/wiki/Q18031208","display_name":"ROS1","level":4,"score":0.6161067485809326},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5503482222557068},{"id":"https://openalex.org/C3020493868","wikidata":"https://www.wikidata.org/wiki/Q55631277","display_name":"Real world data","level":2,"score":0.5002834796905518},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44203898310661316},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.43816155195236206},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30847638845443726},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.151811420917511},{"id":"https://openalex.org/C2522767166","wikidata":"https://www.wikidata.org/wiki/Q2374463","display_name":"Data science","level":1,"score":0.12188678979873657},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.11751821637153625},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.10506793856620789},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.07493749260902405},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:oai:figshare.com:article/24936807","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_materials_Comparative_effectiveness_analysis_between_entrectinib_clinical_trial_and_crizotinib_real-world_data_in_i_ROS1_i_NSCLC/24936807","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.24936807","doi":"https://doi.org/10.6084/m9.figshare.24936807","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.24936807","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.24936807.v1","doi":"https://doi.org/10.6084/m9.figshare.24936807.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.24936807.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"pmh:oai:figshare.com:article/24936807","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_materials_Comparative_effectiveness_analysis_between_entrectinib_clinical_trial_and_crizotinib_real-world_data_in_i_ROS1_i_NSCLC/24936807","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9391000270843506}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3193977597","https://openalex.org/W2981403738","https://openalex.org/W6926817145","https://openalex.org/W2947072829","https://openalex.org/W3138084973","https://openalex.org/W4214916868","https://openalex.org/W4404214345","https://openalex.org/W3042002926","https://openalex.org/W3110662873","https://openalex.org/W3112926054"],"abstract_inverted_index":{"These":[0],"are":[1],"supplementary":[2],"materials":[3],"for":[4,43,81,147,209,214],"the":[5,23,59,70,90,126],"article":[6],"'Comparative":[7],"effectiveness":[8],"analysis":[9,88,95],"between":[10],"entrectinib":[11,224],"clinical":[12,241],"trial":[13],"and":[14,46,78,83,101,175,198],"crizotinib":[15,127,215,232,252],"real-world":[16,182,251],"data":[17],"in":[18,22,69,125,141,240],"ROS1+":[19],"NSCLC'":[20],"published":[21],"Journal":[24],"of":[25,56,58,89,108,118,131],"Comparative":[26],"Effectiveness":[27],"Research.Supplementary":[28],"Materialso":[29],"Censoringo":[30],"Statistical":[31],"methodso":[32],"Sensitivity":[33,87],"analyseso":[34],"Unadjusted":[35],"resultso":[36],"Propensity":[37,50],"scoreSupplementary":[38],"Table":[39,48,53,72,85,92,103],"1.":[40,115],"Censoring":[41],"rules":[42],"TTD,":[44],"PFS,":[45],"OS.Supplementary":[47],"2.":[49],"score":[51],"matching.Supplementary":[52],"3.":[54],"Comparison":[55],"results":[57],"Cox":[60,106],"pro-portional":[61],"hazard":[62,217],"model":[63,107],"using":[64],"BICR":[65],"or":[66],"investigator-assessed":[67],"progression":[68,123],"trial.Supplementary":[71],"4.":[73],"Landmark":[74],"analyses":[75],"at":[76],"1":[77],"3":[79],"months":[80,208,213],"TTD":[82,100,248],"PFS.Supplementary":[84,102],"5.":[86],"TTD.Supplementary":[91],"6.":[93],"Subgroup":[94],"by":[96,111],"CNS":[97,112],"status:":[98],"unad-justed":[99],"7.":[104],"Multivariate":[105],"treatment":[109,121],"effect":[110],"status.Supplementary":[113],"Figure":[114],"Swimmer":[116],"plot":[117],"patients":[119,133],"receiving":[120],"beyond":[122],"(TBP)":[124],"cohort":[128,184],"(37":[129],"out":[130],"65":[132],"received":[134],"TBP).Summary:":[135],"Aim:":[136],"Generating":[137],"direct":[138],"comparative":[139],"evidence":[140],"prospective":[142],"randomized":[143],"trials":[144,170,242],"is":[145],"difficult":[146],"rare":[148],"diseases.":[149],"Real-world":[150],"cohorts":[151],"may":[152,243],"supplement":[153],"control":[154],"populations.":[155],"Methods:":[156],"Entrectinib-treated":[157],"adults":[158],"with":[159,180,223,231,246],"advanced":[160],"ROS1":[161],"fusion-positive":[162],"NSCLC":[163],"(n":[164,185],"=":[165,186],"94)":[166],"from":[167],"Phase":[168],"I/II":[169],"(ALKA-372-001":[171],"[EudraCT2012-00148-88],":[172],"STARTRK-1":[173],"[NCT02097810],":[174],"STARTRK-2":[176],"[NCT02568267])":[177],"were":[178],"compared":[179],"a":[181,250],"crizotinib-treated":[183],"65).":[187],"Primary":[188],"end":[189,195],"point,":[190],"time-to-treatment":[191],"discontinuation":[192],"(TTD);":[193],"secondary":[194],"points,":[196],"PFS":[197],"OS.":[199],"Results:":[200],"Median":[201,221],"(95%":[202],"CI)":[203],"weighted":[204,228],"TTD:":[205],"12.9":[206],"(9.9\u201317.4)":[207],"entrectinib;":[210],"8.2":[211],"(6.2\u20139.9)":[212],"(weighted":[216],"ratio:":[218],"0.72":[219],"[0.51\u20131.02]).":[220],"OS":[222,230],"was":[225,233],"not":[226],"reached,":[227],"median":[229],"18.5":[234],"(15.1\u201347.2)":[235],"months.":[236],"Conclusion:":[237],"Entrectinib":[238],"administered":[239],"be":[244],"associated":[245],"longer":[247],"than":[249],"population.":[253]},"counts_by_year":[],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2024-04-08T00:00:00"}